The Operation Eyesight Universal Institute for Eye Cancer, L. V. Prasad Eye Institute, Hyderabad, Telangana, India.
Indian J Ophthalmol. 2024 Aug 1;72(8):1150-1155. doi: 10.4103/IJO.IJO_1684_23. Epub 2024 Mar 8.
To study the clinical presentation and treatment outcomes of indocyanine green-enhanced transpupillary thermotherapy (ICG-TTT) for treatment-naïve juxtapapillary retinal capillary hemangioblastoma (JRCH).
A prospective interventional case series. The technique involved ICG dye infusion 45 seconds prior to application of TTT. The main study outcomes were local tumor control, resolution of subretinal fluid (SRF), and improvement in best-corrected visual acuity (BCVA).
Eight eyes of seven patients (5 males and 2 females) were included. The mean age was 26 years (range: 5-56 years). Systemic evaluation revealed von-Hippel Lindau (VHL) disease in five patients. The most common location was the temporal aspect of the optic disc (5 eyes). The mean basal diameter was 2.9 mm (range: 1-8 mm), and tumor thickness was 1.4 mm (range: 1-4 mm). All eight eyes were treated with multiple sessions of ICG-TTT (mean: 3 sessions). Six eyes received adjuvant intravitreal injection of dexamethasone implant (4 eyes) and/or bevacizumab (4 eyes). Post treatment, six eyes (75%) had tumor regression with reduction of SRF. One eye had a partial response with persisting SRF, and one eye showed poor response to TTT for which external beam radiotherapy was performed. At the last follow-up (median: 11 months; range: 6-29 months), the BCVA remained stable in seven eyes and improved in one eye (hand motion to 20/40).
Multiple ICG-TTT sessions can be considered as an alternative treatment option for JRCH with effective local tumor control and SRF resolution.
研究吲哚菁绿增强经瞳孔温热疗法（ICG-TTT）治疗未经治疗的神经周围视网膜毛细血管血管瘤（JRCH）的临床表现和治疗结果。
前瞻性干预性病例系列。该技术涉及在应用 TTT 前 45 秒内注入 ICG 染料。主要研究结果是局部肿瘤控制、视网膜下液（SRF）消退和最佳矫正视力（BCVA）改善。
纳入了 7 名患者（5 名男性和 2 名女性）的 8 只眼。平均年龄为 26 岁（范围：5-56 岁）。系统评估显示 5 名患者患有 von-Hippel Lindau（VHL）病。最常见的位置是视盘的颞侧（5 只眼）。平均基底直径为 2.9 毫米（范围：1-8 毫米），肿瘤厚度为 1.4 毫米（范围：1-4 毫米）。所有 8 只眼均接受多次 ICG-TTT 治疗（平均 3 次）。6 只眼接受了曲安奈德植入物（4 只眼）和/或贝伐单抗（4 只眼）的辅助玻璃体内注射。治疗后，6 只眼（75%）的肿瘤缩小，SRF 减少。1 只眼的 SRF 持续存在，部分反应良好，1 只眼对 TTT 反应不佳，行外照射放疗。在最后一次随访（中位数：11 个月；范围：6-29 个月）时，7 只眼的 BCVA 保持稳定，1 只眼改善（手动视力至 20/40）。
多次 ICG-TTT 治疗可被视为 JRCH 的一种替代治疗选择，可有效控制局部肿瘤和消退 SRF。
